Cancer Immunotherapy in the COVID-19 Pandemic Era
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 1 October 2024 | Viewed by 717
Special Issue Editors
Interests: virus–host interactions; respiratory infections; oncolytic viruses; immunotherapy; cancer therapy
Interests: molecular immunorheumatology; autoimmunity; immunometabolism; cancer-like behavior; cancer immunotherapy
Special Issue Information
Dear Colleagues,
The recent coronavirus disease-19 (COVID-19) pandemic, in addition to posing direct threats to health as well as economic and social pressures, has directly affected the management and treatment of other diseases. Among these, cancer immunotherapy regimens, as an effective method of treating different malignancies, have been affected by the widespread infections caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Patients treated through different immunotherapy routes have shown a range of responses, from recovery to severe forms of disease and even death due to COVID-19. However, in the wider context of immunotherapy, beyond those applied to cancer, different immunotherapies for the potential and actual treatment of infections have been proposed, especially during the recent pandemic.
This Special Issue aims to investigate the bilateral effects of the COVID-19 pandemic and the processes of different immunotherapies with respect to the aforementioned concerns.
We welcome original and clinical studies and reviews that investigate stimulation of the immune system to treat cancer or the improvement of the immune system's natural ability to fight cancer. These studies may also incorporate aspects of virology, epidemiology, data analytics, public health, and other related fields.
We look forward to receiving your contributions.
Dr. Amir Sasan Mozaffari Nejad
Dr. Mohammad Javad Mousavi
Dr. Mohsen Keshavarz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- vaccine
- COVID-19
- SARS-CoV-2
- cancer immunotherapy
- immune checkpoint
- patient outcome assessment
- antibodies
